Literature DB >> 23532831

Lynch syndrome: the patients' perspective.

Jurgen Seppen1, Linda Bruzzone.   

Abstract

People with Lynch syndrome have a high lifetime risk for the development of colorectal, endometrial and several other types of cancer. Lynch syndrome is caused by germline mutations in genes encoding DNA mismatch repair proteins. In this review, issues that concern Lynch patients are highlighted from the patients' perspective. Both authors are affected by Lynch syndrome and are active in Lynch patient organizations. The goal of this review is to assist heath care providers in the improvement of care for individuals who share our disorder. Institutional and/or national guidelines that should lead to the identification of Lynch patients have been developed in many countries. However, adherence to these guidelines is poor and the consequence is severe underdiagnosis of Lynch syndrome. An important task of patient organizations is therefore to increase awareness of Lynch syndrome among the general public and health care providers. Because diagnosis of Lynch syndrome based on family history is difficult, the use of molecular and or histological techniques that permit unequivocal diagnosis should be more aggressively promoted. Since Lynch syndrome encompasses a broad spectrum of cancers, a multidisciplinary treatment and screening protocol for all Lynch patients is necessary. Lynch patients must be seen by a team of specialists that are knowledgeable in the various manifestations of Lynch syndrome. Because tumors with mismatch repair deficiency have specific properties, identification of effective chemotherapy regimens, specifically targeted to patients with deficiencies in DNA repair mechanisms, must be developed. The high lifetime risk of developing cancer in Lynch patients warrants lifestyle advice and research into chemopreventive measures that reduce the risk of cancer in this vulnerable group. Implementation of these recommendations will result in greatly improved quality of life for people affected with Lynch syndrome, it is therefore important that health care providers and patient organizations work together to achieve these goals.

Entities:  

Mesh:

Year:  2013        PMID: 23532831     DOI: 10.1007/s10689-013-9630-2

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  22 in total

Review 1.  The multiethnic cohort study: exploring genes, lifestyle and cancer risk.

Authors:  Laurence N Kolonel; David Altshuler; Brian E Henderson
Journal:  Nat Rev Cancer       Date:  2004-07       Impact factor: 60.716

Review 2.  Hormonal contraception and risk of endometrial cancer: a systematic review.

Authors:  Alfred O Mueck; Harald Seeger; Thomas Rabe
Journal:  Endocr Relat Cancer       Date:  2010-09-23       Impact factor: 5.678

3.  Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.

Authors:  Coralie Dorard; Aurélie de Thonel; Ada Collura; Laetitia Marisa; Magali Svrcek; Anaïs Lagrange; Gaetan Jego; Kristell Wanherdrick; Anne Laure Joly; Olivier Buhard; Jessica Gobbo; Virginie Penard-Lacronique; Habib Zouali; Emmanuel Tubacher; Sylvain Kirzin; Janick Selves; Gérard Milano; Marie-Christine Etienne-Grimaldi; Leila Bengrine-Lefèvre; Christophe Louvet; Christophe Tournigand; Jérémie H Lefèvre; Yann Parc; Emmanuel Tiret; Jean-François Fléjou; Marie-Pierre Gaub; Carmen Garrido; Alex Duval
Journal:  Nat Med       Date:  2011-09-25       Impact factor: 53.440

4.  The search for unaffected individuals with Lynch syndrome: do the ends justify the means?

Authors:  Heather Hampel; Albert de la Chapelle
Journal:  Cancer Prev Res (Phila)       Date:  2011-01

5.  One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.

Authors:  Hans F A Vasen; Mohamed Abdirahman; Richard Brohet; Alexandra M J Langers; Jan H Kleibeuker; Mariette van Kouwen; Jan Jacob Koornstra; Henk Boot; Annemieke Cats; Evelien Dekker; Silvia Sanduleanu; Jan-Werner Poley; James C H Hardwick; Wouter H de Vos Tot Nederveen Cappel; Andrea E van der Meulen-de Jong; T Gie Tan; Maarten A J M Jacobs; Faig Lall A Mohamed; Sijbrand Y de Boer; Paul C van de Meeberg; Marie-Louise Verhulst; Jan M Salemans; Nico van Bentem; B Dik Westerveld; Juda Vecht; Fokko M Nagengast
Journal:  Gastroenterology       Date:  2010-03-02       Impact factor: 22.682

6.  Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.

Authors:  Tuan A Dinh; Benjamin I Rosner; James C Atwood; C Richard Boland; Sapna Syngal; Hans F A Vasen; Stephen B Gruber; Randall W Burt
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-18

7.  Simplified identification of Lynch syndrome: a prospective, multicenter study.

Authors:  Delphine Bonnet; Janick Selves; Christine Toulas; Marie Danjoux; Jean Pierre Duffas; Guillaume Portier; Sylvain Kirzin; Laurent Ghouti; Nicolas Carrère; Bertrand Suc; Laurent Alric; Karl Barange; Louis Buscail; Thierry Chaubard; Kamran Imani; Rosine Guimbaud
Journal:  Dig Liver Dis       Date:  2012-04-03       Impact factor: 4.088

8.  Underdiagnosis of Lynch syndrome involves more than family history criteria.

Authors:  Hardeep Singh; Rachel Schiesser; Gobind Anand; Peter A Richardson; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2010-03-18       Impact factor: 11.382

9.  Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer.

Authors:  Brenda Diergaarde; Hanneke Braam; Hans F Vasen; Fokko M Nagengast; Goos N P van Muijen; Frans J Kok; Ellen Kampman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-06       Impact factor: 11.382

10.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Authors:  John Burn; Anne-Marie Gerdes; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Moeslein; Sylviane Olschwang; Diane Eccles; D Gareth Evans; Eamonn R Maher; Lucio Bertario; Marie-Luise Bisgaard; Malcolm G Dunlop; Judy W C Ho; Shirley V Hodgson; Annika Lindblom; Jan Lubinski; Patrick J Morrison; Victoria Murday; Raj Ramesar; Lucy Side; Rodney J Scott; Huw J W Thomas; Hans F Vasen; Gail Barker; Gillian Crawford; Faye Elliott; Mohammad Movahedi; Kirsi Pylvanainen; Juul T Wijnen; Riccardo Fodde; Henry T Lynch; John C Mathers; D Timothy Bishop
Journal:  Lancet       Date:  2011-10-27       Impact factor: 79.321

View more
  3 in total

Review 1.  Psychosocial Impact of Lynch Syndrome on Affected Individuals and Families.

Authors:  Polymnia Galiatsatos; Heidi Rothenmund; Sylvie Aubin; William D Foulkes
Journal:  Dig Dis Sci       Date:  2015-03-19       Impact factor: 3.199

Review 2.  100 years Lynch syndrome: what have we learned about psychosocial issues?

Authors:  Eveline M A Bleiker; Mary Jane Esplen; Bettina Meiser; Helle Vendel Petersen; Andrea Farkas Patenaude
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

3.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Authors:  Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill
Journal:  Gut       Date:  2019-11-28       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.